Puzzle over active surveillance for micropapillary thyroid carcinoma

Abstract

It is worth distinguishing between the two strategies of management for low risk micropapillary thyroid cancer (MPTC). Immediate therapy, whereas active surveillance (AS) entails delivering curative treatment on signs of disease progression. AS appears to reduce overtreatment in patients with low-risk MPTC without compromising cancer-specific survival at 10 years. Therefore, AS is an option for select patients who want to avoid the side-effects inherent to the different types of immediate treatment. However, inclusion criteria for AS and the most appropriate method of monitoring patients on AS have not yet been standardized.

Evaluating the effectiveness of targeted therapies for thyroid carcinoma: an updated meta-analysis

“…Thyroid carcinoma is the most common malignant tumor of the endocrine system, and has shown the fastest growing incidence in recent years, with age standardized (world population) rates of 6.10 and 1.90 per 100,000 persons (15). Thyrotropin (TSH) inhibition or RAI treatment after surgery, can have the most benefit as a routine treatment for thyroid carcinoma, with the 5-year survival rate of patients with thyroid carcinoma increasing to 97.8% (16). However, 7-23% of patients develop distant metastases (17), and so there are still a large number of refractory thyroid carcinomas, such as advanced, recurrent, metastatic thyroid, medullary, and anaplastic thyroid carcinoma.…”

Meta Analysis of the Outcomes in Doing Active Surveillance and Surgical Approach for Micropapillary Thyroid Carcinoma

“…Despite these results, active surveillance has yet to become widely accepted. Progression on its clinical stage remains an absolute switch to surgical intervention [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. Therefore, this meta analysis aim to determine results in doing active surveillance and surgical approach for micropapillary thyroid carcinoma.…”